Loading company…
SciRhom develops therapeutic antibodies targeting iRhom2 for autoimmune diseases.
Founded in 2016, SciRhom is based in Planegg, Germany, and develops antibodies targeting iRhom2, a regulator of inflammatory signaling through TACE. Its research targets conditions including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis. In June 2024, it raised EUR 63.000 mn in Series A funding led by Andera Partners and Kurma Partners to advance its clinical program.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in